MNCs Increasingly Investing In Diseases Affecting Developing Countries – IFPMA
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Underscoring what may be a subtle but ongoing change in focus for the industry, pharmaceutical companies appear to be increasingly focused on chronic diseases, child and maternal health and other issues of developing countriesYou may also be interested in...
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Indian Healthcare Industry To Zoom Past $14 Billion In The Next Three Years; Quadruple By 2017 - KPMG Report
Need a specific report? 1000+ reports available
Buy Reports